ñ-Pyrrolidinohexiophenone (ñ-PHP, A-PHP, Aphp, alpha-PHP, ñ-Pyrrolidinohexanophenone, PV-7) is a synthetic stimulant drug of the cathinone class developed in the 1960s which has been reported as a novel designer drug.
ñ-Pyrrolidinohexiophenone is a longer chain homologue of ñ-PVP, having an extra carbon on the alkyl side chain. Regarding the potency of alpha-PHP in the brain, chemist Michael H. Baumann of the Designer Drug Research Unit (established by Baumann) of the National Institute on Drug Abuse stated: "alpha-PHP might be even more potent than alpha-PVP"; this statement is based on laboratory tests of chemical reactivity.
Pyrovalerone is a structural isomer of alpha-PHP.
The President of the Republic of Italy classified cathinone and all structurally derived analogues (including pyrovalerone analogues) as narcotics in January 2012.
Sweden's public health agency suggested to classify ñ-PHP as narcotic on June 1, 2015.
As of October 2015, ñ-PHP is a controlled substance in China.
In December 2019, the UNODC announced scheduling recommendations placing Alpha-PHP into Schedule II.
As of 29 October 2021, ñ-PHP has been banned in the Netherlands under the 1971 Vienna Convention on Psychotropic Substances.
In the US, a-PHP is a Schedule I controlled substance as of 2022.